ACCELERON PHARMA INC Insider Trading for March 2015
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ACCELERON PHARMA INC for March 2015.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 5.08 | 800 | 4,064 | 25,496 | |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 0.48 | 4,000 | 1,920 | 20,000 | |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.21 | 200 | 8,242 | 16,500 | 16.7 K to 16.5 K (-1.20 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.60 | 100 | 4,160 | 16,700 | 16.8 K to 16.7 K (-0.60 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.13 | 900 | 37,017 | 16,800 | 17.7 K to 16.8 K (-5.08 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.21 | 800 | 32,968 | 20,004 | 20.8 K to 20 K (-3.85 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 5.08 | 800 | 4,064 | 20,804 | 20 K to 20.8 K (+4.00 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.63 | 721 | 30,015 | 20,004 | 20.7 K to 20 K (-3.48 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.07 | 3,279 | 134,669 | 20,725 | 24 K to 20.7 K (-13.66 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 0.48 | 4,000 | 1,920 | 24,004 | 20 K to 24 K (+20.00 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 4,039 | 23,749 | 20,961 | |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 1,461 | 8,591 | 0 | |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.08 | 4,000 | 20,320 | 0 | |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.20 | 220 | 9,064 | 15,000 | 15.2 K to 15 K (-1.45 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.67 | 5,280 | 214,738 | 15,220 | 20.5 K to 15.2 K (-25.76 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 4,039 | 23,749 | 20,500 | 16.5 K to 20.5 K (+24.54 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 1,461 | 8,591 | 16,461 | 15 K to 16.5 K (+9.74 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 42.05 | 800 | 33,640 | 15,000 | 15.8 K to 15 K (-5.06 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.28 | 3,200 | 132,096 | 15,800 | 19 K to 15.8 K (-16.84 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.08 | 4,000 | 20,320 | 19,000 | 15 K to 19 K (+26.67 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 1,500 | 5,820 | 90,751 | |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 92,251 | |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 40.94 | 200 | 8,188 | 25,000 | 25.2 K to 25 K (-0.79 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 40.14 | 1,300 | 52,182 | 25,200 | 26.5 K to 25.2 K (-4.91 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 1,500 | 5,820 | 26,500 | 25 K to 26.5 K (+6.00 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 40.93 | 619 | 25,336 | 25,000 | 25.6 K to 25 K (-2.42 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 40.16 | 4,381 | 175,941 | 25,619 | 30 K to 25.6 K (-14.60 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 5,000 | 19,400 | 30,000 | 25 K to 30 K (+20.00 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 40.93 | 2,501 | 102,366 | 27,584 | 30.1 K to 27.6 K (-8.31 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 40.15 | 17,499 | 702,585 | 30,085 | 47.6 K to 30.1 K (-36.77 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 5,500 | 32,340 | 1,461 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.08 | 2,000 | 10,160 | 4,000 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 1.80 | 2,000 | 3,600 | 0 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 42.06 | 101 | 4,248 | 15,000 | 15.1 K to 15 K (-0.67 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.77 | 1,066 | 44,527 | 15,101 | 16.2 K to 15.1 K (-6.59 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.34 | 4,333 | 174,793 | 16,167 | 20.5 K to 16.2 K (-21.14 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 5,500 | 32,340 | 20,500 | 15 K to 20.5 K (+36.67 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 42.07 | 1 | 42 | 15,000 | 15 K to 15 K (-0.01 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.50 | 1,300 | 53,950 | 15,001 | 16.3 K to 15 K (-7.97 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.65 | 2,699 | 109,714 | 16,301 | 19 K to 16.3 K (-14.21 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.08 | 2,000 | 10,160 | 19,000 | 17 K to 19 K (+11.76 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 1.80 | 2,000 | 3,600 | 17,000 | 15 K to 17 K (+13.33 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 3,500 | 20,580 | 0 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 500 | 2,940 | 0 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 42.04 | 100 | 4,204 | 33,200 | 33.3 K to 33.2 K (-0.30 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 41.09 | 366 | 15,039 | 33,300 | 33.7 K to 33.3 K (-1.09 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 40.62 | 1,034 | 42,001 | 33,666 | 34.7 K to 33.7 K (-2.98 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 42.06 | 300 | 12,618 | 34,700 | 35 K to 34.7 K (-0.86 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 41.22 | 1,614 | 66,529 | 35,000 | 36.6 K to 35 K (-4.41 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 40.56 | 2,086 | 84,608 | 36,614 | 38.7 K to 36.6 K (-5.39 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 3,500 | 20,580 | 38,700 | 35.2 K to 38.7 K (+9.94 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 5.88 | 500 | 2,940 | 35,200 | 34.7 K to 35.2 K (+1.44 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | A | 41.01 | 15,000 | 615,150 | 15,000 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 5.08 | 1,600 | 8,128 | 26,296 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 0.48 | 4,000 | 1,920 | 24,000 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.38 | 300 | 12,414 | 17,700 | 18 K to 17.7 K (-1.67 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 40.63 | 700 | 28,441 | 18,000 | 18.7 K to 18 K (-3.74 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 40.92 | 400 | 16,368 | 18,700 | 19.1 K to 18.7 K (-2.09 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 40.21 | 1,600 | 64,336 | 20,004 | 21.6 K to 20 K (-7.41 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 5.08 | 1,600 | 8,128 | 21,604 | 20 K to 21.6 K (+8.00 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 42.07 | 200 | 8,414 | 20,004 | 20.2 K to 20 K (-0.99 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.40 | 1,001 | 41,441 | 20,204 | 21.2 K to 20.2 K (-4.72 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 40.66 | 2,799 | 113,807 | 21,205 | 24 K to 21.2 K (-11.66 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 0.48 | 4,000 | 1,920 | 24,004 | 20 K to 24 K (+20.00 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | A | 41.01 | 30,000 | 1,230,300 | 30,000 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 5.08 | 3,906 | 19,842 | 2,344 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 1.80 | 1,094 | 1,969 | 0 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 42.05 | 400 | 16,820 | 52,656 | 53.1 K to 52.7 K (-0.75 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 41.28 | 2,043 | 84,335 | 53,056 | 55.1 K to 53.1 K (-3.71 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 40.54 | 2,557 | 103,661 | 55,099 | 57.7 K to 55.1 K (-4.43 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 5.08 | 3,906 | 19,842 | 57,656 | 53.8 K to 57.7 K (+7.27 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 1.80 | 1,094 | 1,969 | 53,750 | 52.7 K to 53.8 K (+2.08 %) |